521 related articles for article (PubMed ID: 28513830)
21. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
22. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
24. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
25. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
[TBL] [Abstract][Full Text] [Related]
26. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
27. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
[TBL] [Abstract][Full Text] [Related]
28. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
29. Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
Li L; Ni BB; Zhong QH; Liu YH; Zhang MH; Zhang KP; Chen DC; Wang L
Future Oncol; 2017 Jul; 13(17):1473-1492. PubMed ID: 28685592
[TBL] [Abstract][Full Text] [Related]
30. Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer.
Lee DW; Han SW; Kang JK; Bae JM; Kim HP; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Ann Surg Oncol; 2018 Oct; 25(11):3389-3395. PubMed ID: 30062471
[TBL] [Abstract][Full Text] [Related]
31. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.
Maus MK; Hanna DL; Stephens CL; Astrow SH; Yang D; Grimminger PP; Loupakis F; Hsiang JH; Zeger G; Wakatsuki T; Barzi A; Lenz HJ
Pharmacogenomics J; 2015 Aug; 15(4):354-62. PubMed ID: 25532759
[TBL] [Abstract][Full Text] [Related]
32. Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors.
Lin JK; Lin PC; Lin CH; Jiang JK; Yang SH; Liang WY; Chen WS; Chang SC
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S680-6. PubMed ID: 24841357
[TBL] [Abstract][Full Text] [Related]
33. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Sasaki Y; Akasu T; Saito N; Kojima H; Matsuda K; Nakamori S; Komori K; Amagai K; Yamaguchi T; Ohue M; Nagashima K; Yamada Y
Cancer Sci; 2016 Jul; 107(7):1006-12. PubMed ID: 27089049
[TBL] [Abstract][Full Text] [Related]
35. Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation.
Osman S; Kahraman Çetin N; Erdoğdu İH; Meteoğlu İ
Turk J Gastroenterol; 2023 Nov; 34(11):1124-1133. PubMed ID: 37737217
[TBL] [Abstract][Full Text] [Related]
36. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
Atreya CE; Sangale Z; Xu N; Matli MR; Tikishvili E; Welbourn W; Stone S; Shokat KM; Warren RS
Cancer Med; 2013 Aug; 2(4):496-506. PubMed ID: 24156022
[TBL] [Abstract][Full Text] [Related]
37. Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes.
Zekri J; Al-Shehri A; Mahrous M; Al-Rehaily S; Darwish T; Bassi S; El Taani H; Al Zahrani A; Elsamany S; Al-Maghrabi J; Sadiq BB
Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218784
[TBL] [Abstract][Full Text] [Related]
38. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome.
Bettstetter M; Berezowska S; Keller G; Walch A; Feuchtinger A; Slotta-Huspenina J; Feith M; Drecoll E; Höfler H; Langer R
Hum Pathol; 2013 May; 44(5):829-36. PubMed ID: 23158210
[TBL] [Abstract][Full Text] [Related]
40. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]